RA0786

antibody from Oursmab

Targeting: TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE

Western blot (Supportive data in Antibodypedia)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0786

Provider

Oursmab

Product name

Narlumosbart (Biosimilar Reference Antibody) (TNFSF11)

Antibody type

Monoclonal

Description

Narlumosbart (also known as Narusuobai Monoclonal Antibody) is a humanized IgG4-kappa monoclonal antibody that specifically targets receptor activator of nuclear factor-¦ÊB ligand (RANKL), a key cytokine involved in bone metabolism and tumor-bone interactions. As an IgG4 isotype, it is engineered to minimize effector functions (e.g., ADCC, CDC) and focus on ligand blockade. By binding to RANKL with high affinity, narlumosbart prevents RANKL from interacting with its receptor RANK on osteoclast precursors and mature osteoclasts, thereby inhibiting osteoclast differentiation, activation, and survival.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Narlumosbart (Biosimilar Reference Antibody) (TNFSF11)-RA0786-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.